LAZARD ASSET MANAGEMENT LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 22 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
LAZARD ASSET MANAGEMENT LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2021$13,769,000
-8.3%
21,000,000
-16.0%
0.02%
-10.5%
Q4 2020$15,009,000
-9.6%
25,000,000
+5.0%
0.02%
-17.4%
Q3 2020$16,598,000
+192.6%
23,800,000
+205.1%
0.02%
+155.6%
Q2 2020$5,673,000
-36.4%
7,800,000
-24.3%
0.01%
-43.8%
Q1 2020$8,917,000
-35.1%
10,300,0000.0%0.02%
-20.0%
Q4 2019$13,731,000
-5.0%
10,300,000
-35.6%
0.02%
-16.7%
Q3 2019$14,460,000
+41.8%
16,000,000
+56.0%
0.02%
+41.2%
Q2 2019$10,198,00010,255,0000.02%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
HIGHBRIDGE CAPITAL MANAGEMENT LLC 55,943,000$34,742,0001.33%
PenderFund Capital Management Ltd. 5,000,000$3,839,0000.98%
Context Capital Management, LLC 7,485,000$4,494,0000.62%
Opti Capital Management, LP 7,000,000$4,250,0000.47%
Soros Fund Management 32,298,000$19,611,0000.37%
Shaolin Capital Management LLC 7,000,000$4,175,0000.29%
Weiss Asset Management LP 3,500,000$2,084,0000.09%
CSS LLC/IL 2,825,000$1,681,0000.06%
GABELLI & Co INVESTMENT ADVISERS, INC. 225,000$137,0000.02%
LAZARD ASSET MANAGEMENT LLC 25,000,000$15,009,0000.02%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders